STING Ligands

Cyclic dinucleotides and xanthenone derivative

Cyclic dinucleotides

Cyclic dinucleotides (CDNs) and the xanthenone derivative DMXAA, were recently found to bind to and activate STING, leading to a potent type I IFN response.
CDNs are important messengers in bacteria, affecting numerous responses of the prokaryotic cell, but also in mammalian cells, acting as agonists of the innate immune response.

CDNs represent a promising new class of vaccine adjuvants. To assist your research needs, InvivoGen provides a large collection of CDNs available in two grades:
- InvivoGen Standard Grade: purity ≧ 95%, validated using cell-based assays;
- VacciGrade™: sterility guaranteed and endotoxin level < 1 EU/mg, in addition to the above-mentioned criteria.

Natural CDNs

2’3’-cGAMPMammalian (non-canonical) CDN, cyclic [G(2’,5’)pA(3’,5’)p] 500 µg
1 mg
5 mg
2’3’-cGAMP VacciGrade™STING-based vaccine adjuvant, Th1/Th2 response1 mg
3'3'-cGAMPBacterial (canonical) CDN, cyclic [G(3’,5’)pA(3’,5’)p] 500 µg
1 mg
3’3’-cGAMP VacciGrade™STING-based vaccine adjuvant, Th1/Th2 response1 mg
c-di-AMPBacterial (canonical) CDN, cyclic [A(3’,5’)pA(3’,5’)p]1 mg
c-di-AMP VacciGrade™STING-based vaccine adjuvant, Th1/Th2 response1 mg
c-di-GMPBacterial (canonical) CDN, cyclic [G(3’,5’)pG(3’,5’)p]1 mg
c-di-GMP VacciGrade™STING-based vaccine adjuvant, Th1/Th2 response1 mg

cAIM-derived CDNs

cAIMP NEWCyclic (adenine monophosphate- inosine monophosphate)500 µg
cAIMP Difluor NEWcAIMP difluorinated250 µg
cAIM(PS)2 Difluor (Rp/Sp) NEWcAIMP bisphosphorothioate and difluorinated100 µg

cGAMP-derived CDNs

2’2’-cGAMPCyclic [G(2’,5’)pA(2’,5’)p] 500 µg
1 mg
2’3’-cGAM(PS)2 (Rp/Sp)Bisphosphorothioate analog of 2'3'-cGAMP, (Rp/Sp) cyclic [G(2’,5’)psA(3’,5’)ps]250 µg
3'3'-cGAMP FluorinatedDifluoro 3'3'-cGAMP, cyclic [FdG(3’,5’)pFdA(3’,5’)p]100 µg

c-di-AMP-derived CDNs

c-di-AMP FluorinatedDifluoro 3'3'-c-di-AMP, cyclic [FdA(3’,5’)pFdA(3’,5’)p]100 µg
2'3'-c-di-AMPCyclic [A(2’,5’)pA(3’,5’)p]500 µg
2’3’-c-di-AM(PS)2 (Rp,Rp)Bisphosphorothioate analog of 2'3'-c-di-AMP, (Rp;Rp) cyclic [A(2’,5’)psA(3’,5’)ps] 100 µg
500 µg
2’3’-c-di-AM(PS)2 (Rp,Rp) VacciGrade™ NEWSTING-based vaccine adjuvant, Th1/Th2 response500 µg

c-di-GMP-derived CDNs

c-di-GMP FluorinatedDifluoro 3'3'-c-di-GMP, cyclic [FdG(3’,5’)pFdG(3’,5’)p]100 µg
2’3’-c-di-GMP NEWCyclic [G(2’,5’)pG(3’,5’)p]500 µg

c-di-IMP-derived CDNs

c-di-IMPCyclic [I(3’,5’)pI(3’,5’)p]1 mg

Control CDNs

2'3'-cGAMP Control2'3'-cGAMP negative control1 mg
3'3'-cGAMP Control3'3'-cGAMP negative control1 mg
c-di-AMP Controlc-di-AMP negative control1 mg
c-di-GMP Controlc-di-GMP negative control1 mg
c-di-UMPc-di-IMP negative control1 mg

Xanthenone Analog

DMXAAVadimezan, ASA404, murine STING ligand5 mg
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "www.invivogen.com".